Abstract
Ramucirumab (IMC-1121B) is a fully humanized monoclonal antibody that binds to VEGFR2 and can inhibit angiogenesis, a quintessential mechanism for promoting tumor growth and metastasis. Several antiangiogenesis agents are already approved for cancer therapy; however, ramucirumab's selectivity for VEGFR2 makes it interesting. The selectivity of an agent can improve safety and efficacy. This article describes the mechanism of action, pharmacokinetics, safety and clinical trial results of ramucirumab with particular emphasis on gastric cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Clinical Trials as Topic
-
Humans
-
Neovascularization, Pathologic / drug therapy*
-
Ramucirumab
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / immunology
-
Vascular Endothelial Growth Factor A / genetics
-
Vascular Endothelial Growth Factor A / therapeutic use
-
Vascular Endothelial Growth Factor Receptor-2 / genetics
-
Vascular Endothelial Growth Factor Receptor-2 / immunology*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factor Receptor-2